PHARMANUTRA SPA (PHN.MI) Stock Price, Quote, News and Overview
BIT:PHN - Euronext Milan - IT0005274094 - Common Stock - Currency: EUR
PHN.MI Quote, Performance and Key Statistics
BIT:PHN (6/16/2025, 3:34:27 PM)
47.675
-0.03 (-0.05%)
The current stock price of PHN.MI is 47.675 EUR. In the past month the price decreased by -7.74%. In the past year, price increased by 3.58%.
PHN.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| OR.PA | L'OREAL | 29.46 | 199.30B | ||
| LOR.DE | L'OREAL | 29.32 | 198.31B | ||
| UNA.AS | UNILEVER PLC | 23.83 | 133.82B | ||
| UNVB.DE | UNILEVER PLC | 23.83 | 133.82B | ||
| BEI.DE | BEIERSDORF AG | 27.4 | 27.23B | ||
| 1ELX.MI | ESTEE LAUDER COMPANIES-CL A | 29.51 | 21.87B | ||
| COTY.PA | COTY INC-CL A | 20.35 | 3.73B | ||
| ITP.PA | INTERPARFUMS SA | 20.22 | 2.88B | ||
| ICOS.MI | INTERCOS SPA | 28.89 | 1.31B | ||
| ONTEX.BR | ONTEX GROUP NV | 62.58 | 618.45M | ||
| JBOG.PA | JACQUES BOGART | N/A | 78.45M | ||
| ENV.MI | ENERVIT | 14.09 | 57.67M |
Related stock screener links
About PHN.MI
Company Profile
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa and currently employs 115 full-time employees. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Company Info
PHARMANUTRA SPA
Via delle Lenze n. 216/B
Pisa PISA IT
Employees: 115
Phone: 390507846500
PHARMANUTRA SPA / PHN.MI FAQ
What is the stock price of PHARMANUTRA SPA today?
The current stock price of PHN.MI is 47.675 EUR. The price decreased by -0.05% in the last trading session.
What is the ticker symbol for PHARMANUTRA SPA stock?
The exchange symbol of PHARMANUTRA SPA is PHN and it is listed on the Euronext Milan exchange.
On which exchange is PHN.MI stock listed?
PHN.MI stock is listed on the Euronext Milan exchange.
What is the price forecast or stock price prediction for PHARMANUTRA SPA stock?
7 analysts have analysed PHN.MI and the average price target is 83.64 EUR. This implies a price increase of 75.44% is expected in the next year compared to the current price of 47.675. Check the PHARMANUTRA SPA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PHARMANUTRA SPA worth?
PHARMANUTRA SPA (PHN.MI) has a market capitalization of 461.49M EUR. This makes PHN.MI a Small Cap stock.
How many employees does PHARMANUTRA SPA have?
PHARMANUTRA SPA (PHN.MI) currently has 115 employees.
What are the support and resistance levels for PHARMANUTRA SPA (PHN.MI) stock?
PHARMANUTRA SPA (PHN.MI) has a support level at 47.15 and a resistance level at 50.3. Check the full technical report for a detailed analysis of PHN.MI support and resistance levels.
Is PHARMANUTRA SPA (PHN.MI) expected to grow?
The Revenue of PHARMANUTRA SPA (PHN.MI) is expected to grow by 14.39% in the next year. Check the estimates tab for more information on the PHN.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PHARMANUTRA SPA (PHN.MI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PHN.MI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PHN.MI, evaluating the profitability, health, valuation and growth aspects
- PHARMANUTRA SPA (PHN.MI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PHARMANUTRA SPA (PHN.MI) Sales and EPS estimates to see what analysts future expectations are.
- PHARMANUTRA SPA (PHN.MI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PHARMANUTRA SPA (PHN.MI) Insider and Institutional Ownership to learn about the owners and their transactions.
- PHARMANUTRA SPA (PHN.MI) Stock Chart to make your own analysis
- PHARMANUTRA SPA (PHN.MI) Latest news and press-releases to stay up to date.
Does PHARMANUTRA SPA (PHN.MI) stock pay dividends?
PHARMANUTRA SPA (PHN.MI) has a dividend yield of 2.02%. The yearly dividend amount is currently 0.85. Check the full fundamental report for a detailed analysis of PHN.MI dividend history, reliability and sustainability.
What is the Price/Earnings (PE) ratio of PHARMANUTRA SPA (PHN.MI)?
The PE ratio for PHARMANUTRA SPA (PHN.MI) is 19.7. This is based on the reported non-GAAP earnings per share of 2.42 and the current share price of 47.675 EUR. Check the full fundamental report for a full analysis of the valuation metrics for PHN.MI.
PHN.MI Technical Analysis
PHN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI. Both the health and profitability get an excellent rating, making PHN.MI a very profitable company, without any liquidiy or solvency issues.
PHN.MI Financial Highlights
Over the last trailing twelve months PHN.MI reported a non-GAAP Earnings per Share(EPS) of 2.42. The EPS increased by 29.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.77% | ||
| ROA | 18.91% | ||
| ROE | 36.18% | ||
| Debt/Equity | 0.3 |
PHN.MI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PHN.MI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 16.46% and a revenue growth 14.39% for PHN.MI